Alvotech (ALVO), Kashiv Biosciences, and Advanz Pharma said Wednesday that the UK Medicines and Healthcare Products Regulatory Agency has accepted the marketing application for AVT23, a proposed biosimilar to Xolair.
Xolair is indicated for the treatment of severe persistent allergic asthma and chronic rhinosinusitis, the companies said.
Alvotech and Advanz Pharma have a commercialization agreement for AVT23, while Alvotech and Kashiv have a licensing agreement for AVT23, according to the statement.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.